Skip to main content
. Author manuscript; available in PMC: 2014 May 14.
Published in final edited form as: Mol Carcinog. 2011 Oct 17;51(12):952–962. doi: 10.1002/mc.20866

Figure 1.

Figure 1

Effect of apigenin and HDAC inhibitor TSA on class I HDAC activity in human prostate cancer cells. Panel 1, Dose-dependent inhibition of HDAC activity in PC-3 cells exposed to 20 μM and 40 μM concentrations of apigenin and TSA (20 and 80 ng/ml) for 24 h Panel 2, Dose-dependent inhibition on HDAC activity in 22Rv1 cells after treatment with various concentrations of apigenin (20 μM and 40 μM) and TSA (20 and 80ng/ml) for 24 h. Data represents the mean ± SD of three different assays. **P < 0.001 versus control. The details are provided in ‘materials and methods’.